ImmuPharma plc
IMM.L · LSE
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | £29 | £0 | £45 | £0 |
| Gross Profit | -£29 | £0 | -£45 | £0 |
| % Margin | – | – | – | – |
| R&D Expenses | £345 | £345 | £344 | £344 |
| G&A Expenses | £245 | £245 | £387 | £387 |
| SG&A Expenses | £273 | £273 | £414 | £414 |
| Sales & Mktg Exp. | £28 | £28 | £28 | £28 |
| Other Operating Expenses | -£3 | -£3 | £713 | £197 |
| Operating Expenses | £615 | £615 | £1,471 | £956 |
| Operating Income | -£1,236 | -£615 | -£1,516 | -£956 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -£714 | -£360 | -£668 | -£137 |
| Pre-Tax Income | -£1,949 | -£975 | -£2,185 | -£1,092 |
| Tax Expense | -£110 | £55 | -£89 | -£44 |
| Net Income | -£919 | -£919 | -£1,048 | -£1,048 |
| % Margin | – | – | – | – |
| EPS | -0.002 | -0.002 | -0.003 | -0.003 |
| % Growth | 0% | 24% | 0% | – |
| EPS Diluted | -0.002 | -0.002 | -0.003 | -0.003 |
| Weighted Avg Shares Out | 479,874 | 479,874 | 416,437 | 411,073 |
| Weighted Avg Shares Out Dil | 479,828 | 479,828 | 416,437 | 416,437 |
| Supplemental Information | – | – | – | – |
| Interest Income | £24 | £0 | -£166 | £0 |
| Interest Expense | £743 | £360 | £0 | £83 |
| Depreciation & Amortization | £14 | £14 | £23 | £23 |
| EBITDA | -£601 | -£601 | -£933 | -£933 |
| % Margin | – | – | – | – |